Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia

L. Maria Belalcazar, MD*; Aksam Merched, PhD*; Boyd Carr; Kazuhiro Oka, PhD; Kuang-Hua Chen, PhD; Lucio Pastore, MD, PhD; Arthur Beaudet, MD; Lawrence Chan, MBBS, DSc

Background—Epidemiologic studies and transgenic mouse experiments indicate that high plasma HDL and apolipoprotein (apo) A-I protect against atherosclerosis. We used helper-dependent adenovirus (HD-Ad) gene transfer to examine the effect of long-term hepatic apoA-I expression on atherosclerotic lesion progression and remodeling in a mouse model of familial hypercholesterolemia.

Methods and Results—We treated LDL receptor–deficient (LDLR−/−) mice maintained on a high-cholesterol diet for 6 weeks with either a HD-Ad containing human apoA-I gene (HD-Ad-AI) or saline (control). HD-Ad-AI treatment did not affect plasma liver enzymes but induced the appearance of plasma human apoA-I at or above human levels for the duration of the study. Substantial amounts of human apoA-I existed in lipid-free plasma. Compared with controls, HDLs from treated mice were larger and had a greater inhibitory effect on tumor necrosis factor-α–induced vascular cellular adhesion molecule-1 expression in cultured endothelial cells. Twenty-four weeks after injection, aortic atherosclerotic lesion area in saline-treated mice progressed ~700%; the rate of progression was reduced by >50% by HD-Ad-AI treatment. The lesions in HD-Ad-AI–treated mice contained human apoA-I that colocalized mainly with macrophages; they also contained less lipid, fewer macrophages, and less vascular cellular adhesion molecule-1 immunostaining but more smooth muscle cells (α-actin staining) and collagen.

Conclusions—HD-Ad-AI treatment of LDLR−/− mice leads to long-term overexpression of apoA-I, retards atherosclerosis progression, and remodels the lesions to a more stable-appearing phenotype. HD-Ad–mediated transfer of apoA-I may be a useful clinical approach for protecting against atherosclerosis progression and stabilizing atherosclerotic lesions associated with dyslipidemia in human patients. (Circulation. 2003;107:2726-2732.)

Key Words: gene therapy ■ apolipoproteins ■ hypercholesterolemia ■ atherosclerosis ■ adenovirus

Low HDL cholesterol is the most frequent lipid disorder in patients with coronary artery disease.1 Apolipoprotein A-I (apoA-I) is a major protein component of HDL and plays a pivotal role in its formation. ApoA-I level seems to be a better indicator of coronary risk than HDL cholesterol level.2 Animal studies have demonstrated that elevated plasma apoA-I by protein infusion3 or transgenic overexpression4–7 protects against atherosclerotic progression and may induce lesion regression.

Given the protective role of the APOAI gene, somatic gene transfer of apoA-I is an attractive strategy for the treatment of atherovascular disease. For hepatic transgene expression, adeno-associated virus (AAV) and helper-dependent adenovirus (HD-Ad) are presently the most promising vehicles for experimental gene therapy. AAV is relatively nontoxic but has relatively low transduction efficiency and cloning capacity. For proteins that require high plasma concentrations (in the 1 mg/mL range) to be effective, HD-Ads may be preferred. HD-Ads lack all viral protein coding sequences and seem to be substantially less toxic than earlier generation Ads. They have been reported to express transgenes in vivo in a stable and effective manner.8–13 These advantages and a natural tropism of this vector to the liver prompted us to test the efficacy of

**Methods**

**Construction and Evaluation of HD-Ad-AI**

An 11-kb EcoRI fragment containing the human apoA-I gene was first subcloned into a pLPBL1 vector and then into p/H9004. Rescue and amplification of the HD-Ad-AI were performed by the method of Parks et al. The vector was characterized as described previously.

**Animal Studies**

Animal studies were performed according to Baylor College of Medicine institutional guidelines. Female LDL receptor-deficient (LDLR/-/-) mice on a C57BL/6 background (Jackson Laboratory) were started on a laboratory chow supplemented with 0.2% (wt/wt) cholesterol and 10% coconut oil (vol/wt) at 6 to 9 weeks of age. Six weeks later, a subgroup of mice (n=10) was killed, and the baseline en face aortic lesion size was determined. Thirty-eight mice were then injected via tail vein with HD-Ad-AI (4.5 x 10^12 particles/kg) and 36 mice with an equivalent volume of saline (200 µL). Animals were followed for up to 24 weeks after injection (30 weeks of high-cholesterol diet). Subgroups of animals were killed for quantification of lesions and histological evaluation at 4, 12, and 24 weeks after injection. Blood was collected monthly from the retro-orbital plexus into EDTA-containing tubes after a 5-hour fast and immediately centrifuged to obtain plasma, which was stored at −20°C or at 4°C for analyses.

**Immunohistochemistry, Histology, and Quantitation of Atherosclerotic Lesions**

Immunohistochemical and histological studies were performed on fresh-frozen OCT-embedded proximal aortic sections (5 µm thick). For immunohistochemistry, slides were fixed in cold acetone. They were incubated with either monoclonal anti-human apoA-I or anti-α-actin (Biodesign, 1:100 and Sigma, 1:800, respectively), and the M.O.M. Basic Kit (Vector) was used for detection. Macrophages and vascular cell adhesion molecule-1 (VCAM-1) were detected by immunostaining with MOMA-2 (1:25) or anti-VCAM-1 (1:100) antibody (PharMingen) using Dako EnVision AP or HRP polymer system and a rat-specific kit (Vector). Histology was performed using standard techniques for Oil-Red O, H&E, trichrome, and Van Kossa. Aortic en face lesions were evaluated by quantitative morphometry as previously described. VCAM-1–positive area was assessed in 3 to 4 serial 10-µm sections at 70-µm intervals. After capturing images of the aortic sections, we determined VCAM-1–positive area by computer-assisted color-gated measurement on the total lesion area (SigmaScanPro 5, SPSS).
HDL Modulation of Tumor Necrosis Factor-α–Induced VCAM-1 Expression in Cultured Endothelial Cells

The effect of HDL isolated from control or HD-Ad-AI–treated mice on tumor necrosis factor-α (TNF-α)–induced VCAM-1 expression was tested in cultured human umbilical vein endothelial cells (HUVECs). HDL was isolated by sequential ultracentrifugation using a TL-100 Beckman ultracentrifuge. The purity of fractions was confirmed by lipoprotein agarose electrophoresis. HUVECs were cultured in 96-well tissue culture plates until a density of 1.0 × 10^5 cells/well was reached and then incubated with 0.1 mL of HDL in the presence of 50 U/mL TNF-α (Boehringer Mannheim). HUVEC VCAM-1 expression was determined 3 hours after incubation by ECL.

Statistical Analysis

Data for lesions and VLDL, IDL/LDL, and HDL cholesterols were analyzed by two-way ANOVA with factors time (0, 4, 12, and 24 weeks) and treatment group (HD-Ad-AI versus control). Plasma cholesterol levels were compared across time, within a group by paired t test. Comparisons between groups for plasma lipids and induced VCAM-1 expression were performed by a 2-sample t test. The Wilcoxon rank-sum test was used when appropriate to confirm normality.

Other Procedures

Lipids and FPLC (Amersham Pharmacia Biotech AB) analyses were performed as previously described. Human plasma apoA-I levels were quantitated by an immunoturbidimetric assay (Diasorin). HDL cholesterol was determined from FPLC fractions. Three sets of pooled plasma (200 μL) from control and HD-Ad-AI–treated mice were used for these determinations. For immunoblot analysis, plasma was diluted 1:32, electrophoresed on a 12% SDS-polyacrylamide gel, and transferred to membrane, which was then incubated either with a goat anti-human apoA-I antibody (1:2000 dilution, Chemicon) or with a rabbit anti-mouse apoA-I antibody (1:100 dilution, Biodesign). Immunoreactive proteins were detected by ECL (Amersham Pharmacia Biotech). For HDL particle sizing, the lipoprotein fraction was isolated as described above and subjected to non-denaturing gradient gel electrophoresis on a 4% to 20% polyacrylamide gradient gel. Computer-assisted densitometry with coelectrophoresed molecular size calibrators was used to determine particle size.

Results

Effect of HD-Ad-AI on Total Plasma Cholesterol and ApoA-I in LDLR−/− Mice

HD-Ad-AI vector was characterized by Southern blot analysis, which showed <0.2% helper virus contamination and no detectable DNA rearrangement (data not shown). LDLR−/− mice maintained on an atherogenic diet for 6 weeks had a basal plasma cholesterol of 9.49 ± 2.02 mmol/L (368 ± 74 mg/dL). A single injection (4.5 × 10^12 particles/kg) of HD-Ad-AI led to the appearance of human apoA-I in plasma, which reached a peak of 71.4 ± 26.6 mmol/L (200 ± 75 mg/dL) at 4 weeks. Plasma liver enzymes remained similar in saline and HD-Ad-AI–treated mice (data not shown). The level of apoA-I (42.9 μmol/L) in treated mice remained at or above the normal human range for 24 weeks after injection (Figure 1A). Appearance of human apoA-I in plasma led to a drop in mouse apoA-I concentration in plasma (Figure 1B). Immunohistochemical staining confirmed the expression of human apoA-I in the liver (Figure 1C). Plasma total cholesterol level at the time of the injection was 9.49 ± 2.02 mmol/L. It increased to 12.77 ± 2.97 mmol/L at 4 weeks and stabilized approximately to control level thereafter (10.34 mmol/L, Figure 1D).

Effect of HD-Ad-AI Treatment on Plasma HDL

We characterized the plasma lipoproteins of HD-Ad-AI–treated mice by FPLC. We noted a small but significant increase in the VLDL fraction and a minor lowering of the IDL/LDL peak in HD-Ad-AI–treated mice (Figure 2A). Interestingly, there was little difference in the HDL peak height; there was, however, a shift of the HDL peak to the left, indicating that these animals’ HDL particles were larger than those in controls. We confirmed this size difference by non-denaturing gradient gel electrophoresis (Figure 2B). There was a significant increase in total plasma HDL cholesterol in HD-Ad-AI mice compared with controls at 4 weeks (Figure 2C). We additionally studied the distribution of apoA-I in the FPLC fractions (Figure 2D). In saline-treated mice, essentially all of the mouse apoA-I was found in the HDL fraction. In contrast, a substantial portion of human apoA-I migrated to the HDL fraction. The HDL fraction from control mice was found at a peak of 70.4 ± 22.1 mmol/L (203 ± 68 mg/dL). The HDL peak in HD-Ad-AI mice was closer to that of human HDL, and the apoA-I was detected in the HDL fraction (Figure 2C).

Figure 3. Aortic lesion analyses. A, En face quantification of aortic lesions. B, Saline-treated mice (control) at baseline (before injection); C, Saline-treated mice; D, HD-Ad-AI treated mice. *P<0.015, †P<0.008 (HD-Ad-AI–treated versus control mouse at the indicated time). B, Cross-section of aorta in an HD-Ad-AI–treated mouse 8 weeks after injection (seen with ×200 magnification). Human apoA-I appears in brown without counterstaining. C, Same aortic cross-section as in B with a second immunostaining for macrophage-derived (MOMA-2–positive, bright red) cells. We observed the colocalization of apoA-I staining in macrophage-positive areas. D, Human apoA-I immunostaining (brown) in aortic cross-section of an HD-Ad-AI–treated mouse (seen with ×630 magnification); apoA-I is detected intracellularly and between cells. E, Absence of human apoA-I immunostaining in a cross-section of aorta from a control mouse.
apoA-I was found in the lipoprotein-free fraction of HD-Ad-AI–treated mice (about half of the human apoA-I). HDL has been shown to modulate the expression of adhesion molecules on vascular endothelial cells. We examined the effect of HDL on TNF-α–stimulated VCAM-1 expression in HUVECs in vitro. HDL isolated from saline-treated mice had little or no effect on TNF-α–stimulated VCAM-1 expression in these cells; however, HDL isolated from HD-Ad-AI mice at 4 or 24 weeks strongly inhibited VCAM-1 expression (55/±6% and 56/±3% inhibition, respectively; n=3; *P<0.001 versus TNF-α alone). The culture medium contained 55.0 and 31.4 μmol/L human apoA-I, respectively, for the 4- and 24-week incubations.

Effect of HD-Ad-AI Treatment on Atherosclerosis Development in LDLR−/− Mice

En face lesion analysis demonstrated no difference between the two groups at 4 weeks. At 12 weeks, there was a 34% decrease in mean lesion area in the HD-Ad-AI–treated mice compared with saline-treated controls. The protective effect of apoA-I was even stronger at 24 weeks, when lesion area in the HD-Ad-AI–treated mice was reduced by 50% (Figure 3A). Immunoreactive human apoA-I was localized in the intracellular compartment and colocalized with markers of macrophage lineage, suggesting that it is present within foam cells of macrophage origin (Figures 3B through 3E).

Histology at sequential time points (Figures 4 and 5) demonstrates progression of atherosclerotic lesions from scant intimal fat deposits compatible with type I lesions to complex lesions analogous to type IV and V lesions in humans. No significant difference between the two groups was observed at 4 weeks. At 12 weeks after injection, compared with control mice, the treated mice showed a decrease in foam cells and lipid deposition and a more pronounced fibrotic response. The difference in lipid deposition was even more evident at 24 weeks (30 weeks of high-cholesterol diet). Lesions in control mice showed marked extracellular lipid accumulation, extensive calcium deposits, and disorganization of the collagen-rich extracellular matrix with atheromatous complications in the deep intima. In contrast, treated mice displayed decreased lipid deposition, scant calcium deposits, and a preservation of collagen-rich extracellular matrix integrity suggestive of greater plaque stability.

Immunohistochemistry reveals plaque-stabilizing features in the HD-Ad-AI–treated mice compared with controls (Figure 6). At 8 weeks after treatment, we observed deposition of human apoA-I in plaques of HD-Ad-AI–treated mice but relatively little difference in the distribution of α-actin stain-
ing between treated and control mice (Figure 6A). Even at this early stage, however, there was a clear reduction in VCAM-1 immunostaining (an indirect marker of inflammation) in the plaques of HD-Ad-AI–treated mice compared with controls. VCAM-1 staining was more intense over α-actin staining (smooth muscle) cells. Quantitative morphometry confirmed that VCAM-1–positive area was reduced in the lesion of HDAd-AI–treated mice (Figure 6A, bottom). At 24 weeks after HD-Ad-AI treatment, in addition to a persistent reduction in VCAM-1 staining (Figure 6B, middle), the amount of macrophage (MOMA-2) staining (Figure 6B, left) was also decreased, whereas smooth muscle staining (α-actin, Figure 6B, right) was substantially increased in treated mice.

Discussion

Two studies published previously in Circulation studied the effect of transient apoA-I gene transfer on atherosclerosis development in various mouse models and concluded that short-term hepatic apoA-I expression produced regression of aortic atherosclerosis. Benoit et al used human apoA-I transgenic mice (with concomitant apoE deficiency) as a study model to obtain the longest possible transgene expression. With the first-generation Ad vector used, they had to terminate the experiment after 6 weeks when the transient apoA-I expression declined. They reported that the gene transfer “inhibited fatty streak lesion formation by 56%” (Benoit et al, p 105). Tangirala et al used a second-generation Ad vector in an LDLR−/− mice fed a high-fat high-cholesterol diet to produce plasma cholesterol averaging ≈31 mmol/L to induce massively accelerated fatty streak lesion formation. These authors found a remarkable 70% reduction in en face aortic atherosclerosis lesion area after only 4 weeks of treatment. However, as pointed out by an accompanying editorial, the two studies only suggest that the gene transfer producing transiently elevated apoA-I can reduce the size of “preexisting lesions, at least those with complexity corresponding to American Heart Association

Figure 6. Immunostaining for α-actin, apoA-I, MOMA-2, and VCAM-1 in atherosclerotic lesions 8 weeks (A) and 24 weeks (B) after vector injection. A, VCAM-1, human apoA-I, and α-actin are stained brown. Bottom left, VCAM-1 immunostaining (brown) at higher magnification (×630). Bottom right, Morphometric analysis of VCAM-1 staining. In the histogram, VCAM-1–positive area was determined by computer-assisted measurement and expressed as a percentage of total lesion area per section. B, From left to right: immunostaining of MOMA-2 (macrophage staining, red), VCAM-1 (brown), and α-actin (dark brown) in aortic lesions 24 weeks after treatment with saline (top) or HD-Ad-AI (bottom).
types I and II (ie, fatty streaks)” (Dansky and Fisher, p 1762). These studies confirm the antiatherosclerotic potential of apoA-I, but the conclusions were limited by the short duration of apoA-I transgene expression, and the authors’ analysis was applicable only to the effects of apoA-I on early-stage fatty streaks. In humans, early atherosclerotic lesions may be present in childhood, are clinically silent, and do not necessarily progress to advanced disease. In fact, fatty streaks frequently regress spontaneously. Therefore, the clinical relevance of the previous findings is uncertain.

We believe that our observations on HD-Ad-AI gene transfer in the hypercholesterolemic mice are directly relevant if apoA-I gene therapy ever comes to clinical trials. We followed the effect of apoA-I overexpression until complex lesions developed (~7 months into the study) and found that at this stage, its antiatherosclerotic potential is much more evident than at earlier time points during the disease process. Early on, when plasma apoA-I levels peaked at 4 weeks, there was no difference in lesion area between treated mice and controls. At this early time point, little human apoA-I was detected in the vascular wall. These observations suggest that the presence of apoA-I in the vessel wall may be exerting a direct effect on the cells of the lesion against atherosclerotic disease progression. The shift in the distribution of apoA-I toward smaller lipid-poor particles with HD-Ad-AI treatment (Figures 2A and 2D) might facilitate the access of apoA-I to the arterial intima. In addition, there is evidence that human apoA-I may have greater antiatherogenic potential compared with mouse apoA-I.

The expression of adhesion molecules on endothelial cells is thought to be an important component in atherogenesis. TNF-α-induced-VCAM-1 expression in cultured HUVECs was significantly inhibited by the HDL isolated from HD-Ad-AI-treated mice but not from control mice, which suggests that one mechanism of the protective effects of HDL against development of atherosclerosis is inhibition of the interaction between leukocytes and endothelium.

Immunohistochemical analysis demonstrated that apoA-I localized preferentially in the intracellular compartment of macrophage-derived foam cells (Figures 3B through 3D). In addition, HD-Ad-AI treatment led to a more stable-appearing plaque phenotype associated with a decrease in subendothelial lipid deposits and a reduction in macrophage-derived cells and adhesion molecule expression. We also observed an increase in smooth muscle cells on the surface of the lesions (Figures 4 through 6). Similar effects of high levels of plasma apoA-I on the remodeling of atherosclerotic lesions into a more stable-appearing phenotype have been observed in thoracic aortas transplanted from apoE-deficient mice to human apoA-I–overexpressing apoE-deficient mice. The multifaceted beneficial effects of apoA-I on both lesion progression and remodeling strongly suggest that apoA-I gene therapy may be an effective way to inhibit lesion progression as well as to remodel atherosclerotic lesions into a phenotype that is associated with a lower probability of clinical events.

In conclusion, changing the functional properties of plasma HDL by apoA-I gene transfer is an effective way to retard atherosclerotic lesion progression as well as to transform such lesions into a more stable-appearing phenotype. Thus, apoA-I gene therapy using a HD-Ad vector is a promising approach for the treatment of patients with established atherosclerosis. Additional studies along these lines are warranted.

Acknowledgments

This work was supported by grants HL-59314 and HL-16512 from the National Institutes of Health. Dr Merched was supported by Bayer-Pharma France, and Dr Chan was supported by the Betty Rutherford Chair in Diabetes and Endocrinology Research. We thank Merck & Co for providing reagents developed by F. Graham; E. Antonova, M. Merched-Sauvage, E.A. Nour, and C. Dieker for their technical assistance in the study; L. Muehberger from University of Texas Medical Branch for her assistance with aortic histology; M. Finegold for help with histological examination of the liver; and M. Majesky for helpful comments on the manuscript.

References


Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia
L. Maria Belalcazar, Aksam Merched, Boyd Carr, Kazuhiro Oka, Kuang-Hua Chen, Lucio Pastore, Arthur Beaudet and Lawrence Chan

Circulation. 2003;107:2726-2732; originally published online May 12, 2003; doi: 10.1161/01.CIR.0000066913.69844.B2
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/107/21/2726

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/